November 3, 2017
The Master Class XVIII • 2017
Disclaimer
The recommendations provided from the authors were obtained on November 3, 2017. The opinions and recommendations do not necessarily accurately reflect the current state of affairs or the current advice the authors may choose to provide in the same circumstances. Please refer to the current guidelines or the Canadian Association of Gastroenterology (CAG) for up-to-date treatment options.
Learning Objectives
The educational objective of the Mentoring in IBD XVIII program is to increase awareness of current developments and best practices in inflammatory bowel disease (IBD) management, promote collaboration among Canadian gastroenterologists, and optimize treatment of IBD.
Participants in this program will be able to:
- Describe clinically important viral infections associated with IBD, and examine the prevention of infection in the era of biologics and immunosuppressants
- Analyze the conditions under which biologic therapy should (or should not) be stopped during pregnancy and lactation, and discuss preconception counseling to achieve favourable maternal and neonatal outcomes
- Assess the role of biosimilars in IBD therapy, and debate the use of biosimilars in Canada today
- Evaluate the evidence, and discern best practice in the “real world” for combination therapy
- Define all the possible ways to optimize therapy before switching biologics
Viral Infections in IBD
Presented by Deepali Kumar, MD
State-of-the-Art Plenary—Preventing Infection in the Era of Biologics
Pregnancy in IBD: Guidance from the Guidelines
Presented by Professor Ailsa Hart
State-of-the-Art Plenary—Now We Know What to Tell the Mother... Or do we?
Biosimilars: Where are we now?
Presented by Peter Laszlo Lakatos, MD
State-of-the-Art Plenary—How Should Canadian Docs Be Using Biosimilars?
Combination Therapy with Biologics: Does one size fit all?
Presented by Jennifer Jones, MD, courtesy of Professor Siew Ng
State-of-the-Art Plenary—Why Have We Not Finally Figured Out Combination Therapy?
To Switch Or Not To Switch? That is the question...
Presented by Brian G. Feagan, MD
State-of-the-Art Plenary—Maximal Treatment Optimization Before Switching